3 drug policy questions to watch in 2026
The Trump administration has shown strong interest in furthering psychedelics as therapy, and cannabis too.
Whatโs Happening
Okay so The Trump administration has shown strong interest in furthering psychedelics as therapy, and cannabis too.
Politics Politics STAT Plus: The 3 biggest issues to watch in vaccine policy in 2026 By Daniel Payne Pharma Pharma STAT Plus: Major pharma companies may avoid Medicare experimentsโ forced price cuts By John Wilkerson and Elaine Chen D. Diagnosis STAT Plus: Trump moves to require lower drug prices in Medicare By John Wilkerson A STAT Examination A STAT Examination Trump administrationโs plan to shrink vaccine schedule sends health sector scrambling By Daniel Payne , Chelsea Cirruzzo , and Helen Branswell Business Business STAT Plus: Pharmaceutical industry evades drug price transparency, again By Bob Herman STAT Plus: FDA voucher program has become vehicle for political interference in drug review decisions, staffers say By Lizzy Lawrence STAT Plus: Iโm the former head of Pfizer R&D. (shocking, we know)
Iโm worried about biopharmaโs future By John L.
Why This Matters
LaMattina STAT Plus: The Worst Biopharma CEO of 2025 made decisions with tragic consequences By Adam Feuerstein STAT Plus: Data on Humanaโs clinics looked dismal. Then its corporate research machine got to work By Casey Ross and Tara Bannow STAT Plus: RFK Jr.
This is the kind of health news that affects everyday decisions.
The Bottom Line
This story is still developing, and weโll keep you updated as more info drops.
Sound off in the comments.
Originally reported by STAT News
Got a question about this? ๐ค
Ask anything about this article and get an instant answer.
Answers are AI-generated based on the article content.
vibe check: